Big Pharma Deal Shakes Up Pre-Market 🚀

⏰ Set a reminder to join me LIVE @ 11am EST today as I review my top trading ideas for the week in the Market Master’s trading room.

My “tactical trade” idea win streak over the past three weeks has been red-hot 🔥.

I’ve managed to identify several stocks that went on to jump 40% after I alerted them…

I’ve found three stocks that became top movers in the entire market the day I brought them to readers’ attention.

That includes my most recent “tactical” idea from Wednesday, a small biopharma stock that had “several standout features that I love to see.” It surged over 20% that day.

I’m now tuned into another small biotech company that is doing some serious action in the pre-market. 

Have a look at NLS Pharmaceutics AG (NLSP) on your favorite trading platform.

This is one of my favorite little stocks, and both times I’ve written about it, it has gone on to climb 20% within a week, and is surging once again this morning.

It looks like traders are cheering on the merger news that dropped just minutes ago between NLSP and Kadimestem.

As of this writing, shares are already rocking over 50% higher this morning on huge volume (it hit 80%+ at one point!!) 

NLSP is definitely on the radar of some big traders now, so make sure you are watching it today as well.

Right now, you can see the stock has been in a pretty steady decline since August…

Investors seem to have been reacting to NLSP’s struggles to meet the Nasdaq’s listing requirements.

Just last week, though, the company announced that it had officially regained full compliance with those requirements thanks to “successful efforts to improve our balance sheet, including raising new capital and implementing a reverse share split” that was enacted September 27.

The regained compliance is especially important for NLSP because for the last year, it has been considering “a wide range of options with a focus on maximizing shareholder value, including strategic partnerships, out licensing assets of the Company, and other future strategic actions.”

The big news on that front broke on July 29, when the company revealed it had entered into a binding term sheet to merge with Kadimastem Ltd, an Israel-based, clinical stage cell therapy company.

The real purpose of the deal seems to be to bring Kadimastem public on the Nasdaq, similar to a SPAC merger.

You should read the full details in this announcement but the gist is that “Kadimastem is anticipated to become a wholly owned subsidiary of NLS, and Kadimastem's shareholders will acquire an 85% interest in NLS.”

The combined company would operate under the Kadimastem name, and following the transaction, “the parties expect to continue developing NLS's promising, first-in class Dual Orexin Agonist platform ("DOXA") within the merged company. The remaining NLS assets are expected to be divested subject to a contingent value rights ("CVR") agreement, the proceeds of which will be distributed entirely to the current shareholders of NLS.”

Ronen Twito, Kadimastem's Executive Chairman and President, summarized the value proposition:

"The merger with NLS will enhance our visibility to the market as a Nasdaq listed company and strengthen our portfolio with the addition of DOXA. Moreover, as previously reported, our AstroRx® product candidate for Amyotrophic Lateral Sclerosis, also known as ALS, treatment received FDA approval for a Phase IIa multi-site clinical trial in the U.S. In addition, our joint development of a diabetes product with iTolerance, a U.S.-based company, proceeding towards pre-Investigational New Drug submission to the FDA. We believe that the exposure of the merged company to the U.S. capital markets will enable us to develop the company's clinical assets and increase shareholder value."

The announcement said that the deal was expected to be executed in September 2024 and to close before December 31, 2024.

The deal seems to have been hung up by the Nasdaq compliance issues, but in a press release put out by Kadimastem last Tuesday, the company said it was pleased NLSP regained Nasdaq compliance since that “constitutes a significant condition for the completion of the merger transaction.”

It added that “In light of the foregoing, the parties are working to sign a final merger agreement. It intends to complete the merger transaction between the companies in the coming months.”

The activity right now in the pre-market suggests to me that investors may now have confidence that the deal will go through.

I definitely recommend doing your own research on NLSP and the proposed merger…

Good places to start are the company websites of Kadimastem and NLS Pharmaceutics.

And of course, always approach your trading in a responsible manner, remembering that trading is very risky. Nothing is ever guaranteed, so never trade with more than you can afford to lose. 

Please read the full disclaimer at the bottom of this email as well so you are aware of additional risks and considerations. Always have a well-thought-out game plan that takes your personal risk tolerance into consideration.

Bottom line: NLSP is officially back in compliance with the Nasdaq listing requirements, and it looks like investors are very optimistic about the pending merger deal based on pre-market trading today. 

Pay close attention to NLSP today to watch the action unfold!

To Your Success,

Questions or concerns about our products? Email [email protected] © Copyright 2022, RagingBull

*Just so you know, what you're reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let's be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren't what you'd call “typical.”

Just a quick heads up about this ad you're reading—as we’ve said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we received twenty five thousand dollars (cash) from Legends Media for advertising NLS Pharmaceutics for a one day marketing program on November 4, 2024. Previously, we received fifteen thousand dollars from Sica Media for advertising NLS Pharmaceutics AG from a period beginning on October 10 through October 11, 2023. Prior to that, we were paid twelve thousand five hundred dollars from Sica Media for advertising NLS Pharmaceutics AG from a period beginning on September 1 through September 4, 2023 and also fifteen thousand dollars from Sica Media who was compensated by a third party not affiliated with the Company for advertising NLS Pharmaceutics AG from a period beginning on August 22 through August 24, 2023. This was paid by someone else not connected to NLS Pharmaceutics. It might be obvious, but whoever paid for this might own shares and is likely looking to sell some or all of them at any time after we send out this information, which might affect the stock price. We may also buy or sell shares in the company at some point in the future, although neither RagingBull nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as our program ends, though that is not always the case.

Now, diving right into NLS Pharmaceutics might sound exciting. But remember, it’s like venturing into the wilderness—be aware that there's exceptional risk involved in trading. This isn't small potatoes we're talking about; you could lose every dime you put in, so always carefully think about what you’re doing. That’s why they call this trading, after all. We're shining a light on the good stuff about the company here, but it's on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r.

Oh, that brings us to another crucial point—we're not here to tell you (or even recommend) what you should do with your hard-earned money. We’re simply sharing our non-expert thoughts by highlighting some companies we like that could use some help telling their story to more people. We’re obviously biased in our writing. We’re not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as “forward-L00king statements” under the securities acts, so take those with a grain of salt. As with all forecasts, they’re not set in stone, often wrong, and we certainly can’t know where the Company’s earnings, business, or share price will be tomorrow or a year from now.

Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can't wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who's licensed to give you real advice. To be clear, 

Neither Raging Bull nor its owners, employees, or independent contractors are registered as a secur1.ties br0ker-deale.r, br0ker, 1nvest.ment advis0r (IA), or IA rep’s with the SEC, any state securities regulat0ry auth.ority, or any self-regulat0ry organization.

So, that's the scoop! If you're intrigued and want to learn more about the companies we talk about, hit up the SEC's website to dig into their filings and see the full picture.